EUCTR2020-004348-27-DK进行中（未招募）1 期
RESPONSE: A Placebo-controlled, Randomized, Phase 3 Study to Evaluate the Efficacy and Safety of Seladelpar in Patients With Primary Biliary Cholangitis (PBC) and an Inadequate Response to or an Intolerance to Ursodeoxycholic Acid (UDCA) - RESPONSE
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 180
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Subjects must meet all of the following criteria to be eligible for study participation:
- •1. Must have given written informed consent (signed and dated) and any authorizations required by local law
- •2. 18 to 75 years old (inclusive)
- •3. Male or female with a diagnosis of PBC based on any two of the following criteria:
- •a. History of ALP above 1.0× ULN for at least 6 months
- •b. Positive AMA titer (>1:40 on immunofluorescence or M2 positive by enzyme linked immunosorbent assay [ELISA]) or positive PBC-specific antinuclear antibodies (ANAs)
- •c. Documented liver biopsy results consistent with PBC
- •4. UDCA for the past 12 months (stable dose for >3 months prior to screening) OR intolerant to UDCA (last dose of UDCA >3 months prior to screening)
- •5. Laboratory parameters measured by the Central Laboratory at screening:
- •a. ALP =1.67× ULN
- •b. Aspartate aminotransferase (AST) =3× ULN
- •c. ALT =3× ULN
- •d. Total bilirubin =2× ULN
- •e. Estimated glomerular filtration rate (eGFR) >45 mL/min/1.73 m2 (calculated by the Modification of Diet in Renal Disease study equation)
- •f. International normalized ratio (INR) below 1.1× ULN
- •For subjects on anticoagulation therapy, INR must be maintained in the range required for prophylaxis for their specific disease.
- •g. Platelet count =100×103/µL
- •NOTE: PT, INR, and platelets can be performed locally at the Screening
- •Visit, if deemed necessary by the investigator after consultation with the
- •medical monitor, in cases where centrally read samples are deemed
- •6. Females of reproductive potential (refer to Section 8.1.1) must use at least 1 barrier contraceptive and a second effective birth control method during the study and for at least 90 days after the last dose. Male subjects who are sexually active with female partners of reproductive potential must use barrier contraception, and their female partners must use a second effective birth control method during the study and for at least 90 days after the last dose
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 150
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 30
排除标准
- •1. Previous exposure to seladelpar (MBX-8025)
- •2. A medical condition other than PBC that, in the investigator’s opinion, would preclude full participation in the study (e.g, cancer) or confound its results (e.g, Paget’s disease, any active infection)
- •3. Advanced PBC as defined by the Rotterdam criteria (albumin below the lower limit of normal AND total bilirubin above 1.0× ULN)
- •4. Presence of clinically important hepatic decompensation, including the following:
- •a. History of liver transplantation, current placement on liver transplantation list, or current Model for End-Stage Liver Disease (MELD) score =12. For subjects on anticoagulation medication, evaluation of the baseline INR, in concert with their current dose adjustments of their anticoagulant medication, will be taken into account when calculating the MELD score. This will be done in consultation with the medical monitor.
- •b. Complications of portal hypertension, including known esophageal varices, history of variceal bleeds or related interventions (e.g, transjugular intrahepatic portosystemic shunt placement), ascites, and hepatic encephalopathy
- •c. Cirrhosis with complications, including history or presence of spontaneous bacterial peritonitis, hepatocellular carcinoma, or hepatorenal syndrome
- •5. Other chronic liver diseases:
- •a. Current features of autoimmune hepatitis as determined by the investigator based on immunoserology, liver biochemistry, or historic confirmed liver histology
- •b. Primary sclerosing cholangitis determined by the presence of diagnostic cholangiographic findings
- •c. History or clinical evidence of alcoholic liver disease
- •d. History or clinical evidence of alpha-1-antitrypsin deficiency
- •e. History of biopsy confirmed NASH
- •f. History or evidence of Gilbert’s syndrome with elevated total bilirubin
- •g. History or evidence of hemochromatosis
- •h. Hepatitis B, defined as the presence of hepatitis B surface antigen (HBsAg)
- •i. Hepatitis C, defined as the presence of hepatitis C virus (HCV) ribonucleic acid (RNA)
- •j. History, evidence, or high suspicion of hepatobiliary malignancy based on imaging, screening laboratory values, and/or clinical symptoms
- •6. Known history of human immunodeficiency virus (HIV) or positive antibody test at screening
- •7. Clinically important alcohol consumption, defined as more than 2 drink units per day (equivalent to 20 g) in women and 3 drink units per day (equivalent to 30 g) in men, or inability to quantify alcohol intake reliably
- •8. History of malignancy diagnosed or treated, actively or within 2 years, or ongoing evaluation for malignancy; localized treatment of squamous or noninvasive basal cell skin cancers and cervical carcinoma in situ is allowed if appropriately treated prior to screening.
- •9. Treatment with OCA, and fibrates (e.g, bezafibrate, fenofibrate, elafibranor, lanifibranor, pemafibrate, saroglitizar) 6 weeks prior to screening
- •10. Treatment with colchicine, methotrexate, azathioprine, or long-term systemic corticosteroids (>2 weeks) during 2 months prior to screening. See Section 7 for additional medications that may be excluded.
- •11. Treatment with anti-pruritic drugs (e.g, cholestyramine, naltrexone, rifampicin, sertraline, or any experimental approach) must be on a stable dose within 1 month prior to screening
- •12. Treatment with any other investigational therapy or device within 30 days or within 5 half-lives, whichever is longer, prior to screening
- •13. For females, pregnancy or breastfeeding
- •14. Any other condition(s)
研究者
相似试验
进行中（未招募）
1 期
A clinical trial to assess the safety and efficacy of seladelpar in patients with primary biliary cholangitis (PBC) and an inadequate response to or intolerance to ursodeoxycholic acid (UDCA).Primary biliary cholangitis (PBC, formerly known as primary biliary cirrhosis) is a serious and potentially life threatening autoimmune disease of the liver characterized by impaired bile flow (cholestasis) and accumulation of toxic bile acids (BA).MedDRA version: 21.0Level: LLTClassification code 10036680Term: Primary biliary cirrhosisSystem Organ Class: 100000004871EUCTR2020-004348-27-ITCymaBay Therapeutics, Inc.180
进行中（未招募）
1 期
A clinical trial to assess the safety and efficacy of seladelpar in patientswith primary biliary cholangitis (PBC) and an inadequate response to orintolerance to ursodeoxycholic acid (UDCA).Primary biliary cholangitis (PBC, formerly known as primary biliarycirrhosis) is a serious and potentially life threatening autoimmunedisease of the liver characterized by impaired bile flow (cholestasis) and accumulation of toxic bile acids (BA).EUCTR2020-004348-27-ROCymaBay Therapeutics, Inc.180
进行中（未招募）
1 期
A clinical trial to assess the safety and efficacy of seladelpar in patientswith primary biliary cholangitis (PBC) and an inadequate response to orintolerance to ursodeoxycholic acid (UDCA).Primary biliary cholangitis (PBC, formerly known as primary biliarycirrhosis) is a serious and potentially life threatening autoimmunedisease of the liver characterized by impaired bile flow (cholestasis) and accumulation of toxic bile acids (BA).EUCTR2020-004348-27-NLCymaBay Therapeutics, Inc.180
进行中（未招募）
1 期
A clinical trial to assess the safety and efficacy of seladelpar in patientswith primary biliary cholangitis (PBC) and an inadequate response to orintolerance to ursodeoxycholic acid (UDCA).Primary biliary cholangitis (PBC, formerly known as primary biliarycirrhosis) is a serious and potentially life threatening autoimmunedisease of the liver characterized by impaired bile flow (cholestasis) and accumulation of toxic bile acids (BA).EUCTR2020-004348-27-PLCymaBay Therapeutics, Inc.180
进行中（未招募）
1 期
A clinical trial to assess the safety and efficacy of seladelpar in patientswith primary biliary cholangitis (PBC) and an inadequate response to orintolerance to ursodeoxycholic acid (UDCA).Primary biliary cholangitis (PBC, formerly known as primary biliarycirrhosis) is a serious and potentially life threatening autoimmunedisease of the liver characterized by impaired bile flow (cholestasis) and accumulation of toxic bile acids (BA).EUCTR2020-004348-27-HUCymaBay Therapeutics, Inc.180